New hope for transplant patients whose liver cancer returns
NCT ID NCT04204850
Summary
This study is testing if the drug cabozantinib can help control liver cancer that has come back in people who previously had a liver transplant. The drug works by blocking proteins that help cancer tumors grow. About 20 participants will take the drug until it stops working or side effects become too difficult.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.